用于评估乳腺癌免疫治疗效果的生物标志物。 - Suppr | 超能文献

Biomarkers for assessing the effectiveness of immunotherapy in breast cancer.

作者信息

Nixon Mellissa J, Balko Justin M

机构信息

Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232-6307, USA.

出版信息

Biomark Med. 2018 Feb;12(2):97-100. doi: 10.2217/bmm-2017-0408. Epub 2018 Jan 17.

DOI:10.2217/bmm-2017-0408

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Biomarkers for assessing the effectiveness of immunotherapy in breast cancer.用于评估乳腺癌免疫治疗效果的生物标志物。

Biomark Med. 2018 Feb;12(2):97-100. doi: 10.2217/bmm-2017-0408. Epub 2018 Jan 17.

2

Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。

Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.

3

Defining the immunogram of breast cancer: a focus on clinical trials.定义乳腺癌的免疫组谱：以临床试验为重点。

Expert Opin Biol Ther. 2019 May;19(5):383-385. doi: 10.1080/14712598.2019.1598372. Epub 2019 Apr 1.

4

Checkpoint Inhibitors in the Treatment of Breast Cancer.检查点抑制剂在乳腺癌治疗中的应用。

Curr Oncol Rep. 2018 Apr 30;20(7):51. doi: 10.1007/s11912-018-0701-2.

5

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌（TNBC）中肿瘤浸润淋巴细胞（TILs）和程序性死亡配体 1（PD-L1）表达的状态所阐明。

Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.

6

PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.PD-1、PD-L1 和 CTLA-4 在妊娠相关和早发性乳腺癌中的表达：一项比较研究。

Breast. 2017 Oct;35:69-77. doi: 10.1016/j.breast.2017.06.013. Epub 2017 Jun 23.

7

Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.乳腺癌治疗的免疫疗法：检查点阻断、癌症疫苗及联合免疫疗法的未来方向

Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.

8

Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.免疫检查点调节剂、细胞毒性 T 淋巴细胞抗原 4（CTLA-4）和程序性死亡配体 1（PD-L1）在女性乳腺癌中的表达。

PLoS One. 2018 Apr 19;13(4):e0195958. doi: 10.1371/journal.pone.0195958. eCollection 2018.

9

Immunotherapy in triple-negative breast cancer.三阴性乳腺癌的免疫治疗。

Med Oncol. 2017 Dec 18;35(1):13. doi: 10.1007/s12032-017-1071-6.

10

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.三阴性乳腺癌原发肿瘤与配对淋巴结转移灶中 PD-L1 表达的异质性。

BMC Cancer. 2018 Jan 2;18(1):4. doi: 10.1186/s12885-017-3916-y.

引用本文的文献

1

Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes.由不同髓系表型驱动的转移性三阴性乳腺癌对免疫检查点抑制的反应

Commun Med (Lond). 2025 May 17;5(1):180. doi: 10.1038/s43856-025-00860-4.